Publications Archive - Page 2 of 2 - European Myeloma Network

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Main author: Ludwig

DOI: 10.1038/leu.2017.353

Publication date: January 2017

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

Main author: Magarotto

DOI: 10.1182/blood-2015-08-662627

Publication date: January 2016

Connected Trials: EMN01

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.

Main author: Sonneveld

DOI: 10.1182/blood-2014-05-576256.

Publication date: January 2015

European Myeloma Network guidelines for the management of multiple myeloma-related complications

Main author: Terpos

DOI: 10.3324/haematol.2014.117176

Publication date: January 2015

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

Main author: van de Donk

DOI: 10.3324/haematol.2013.100552

Publication date: July 2014

Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network

Main author: Ozaki

DOI: 10.1159/000357394

Publication date: January 2014

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Main author: Engelhardt

DOI: 10.3324/haematol.2013.099358

Publication date: January 2014

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

Main author: Dimopoulos

DOI: 10.1182/blood-2013-05-503862.

Publication date: January 2013

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Main author: Dimopoulos

DOI: 10.1182/blood-2013-05-503862

Publication date: January 2013

Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

Main author: Ross

DOI: 10.3324/haematol.2011.056176

Publication date: February 2012

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Main author: Fayers

DOI: 10.1182/blood-2011-03-341669.

Publication date: January 2011

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Main author: Dimopoulos

DOI: 10.1038/leu.2011.3.

Publication date: January 2011

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Main author: Palumbo

DOI: 10.1182/blood-2011-06-358812

Publication date: January 2011

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

Main author: Engelhardt

DOI: 10.3109/10428194.2010.516378

Publication date: January 2010

A new co-operative group: the European Myeloma Network Trialist Group

DOI: 10.1080/10428190903191874

Publication date: October 2009

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

Main author: Terpos

DOI: 10.1093/annonc/mdn796

Publication date: January 2009

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Main author: Rawstron

DOI: 10.3324/haematol.11080

Publication date: January 2008

European myeloma network: the value of collaborative research

Main author: Sonneveld

DOI: 10.1159/000087039

Publication date: January 2005